GSK: positive data with Eli Lilly in Covid-19

(CercleFinance.com) - Eli Lilly and GlaxoSmithKline (GSK) announce positive first-line data from the expanded phase II BLAZE-4 trial in low-risk adult patients with mild-to-moderate Covid-19.


Results showed that bamlanivimab 700 maintaining, jointly administered with VIR-7831 500 mg, demonstrated a 70% relative reduction in persistently high viral load at day 7 compared to placebo, thereby meeting the primary endpoint.

"In addition, bamlanivimab administered with VIR-7831 demonstrated a statistically significant reduction compared to placebo in the key virologic secondary endpoints," both pharmaceutical companies added.


Copyright (c) 2021 CercleFinance.com. All rights reserved.